Glioblastoma's overexpressed IL-13Rα2, TfR, RTKs, and integrins offer promising targets for nanoparticle-mediated therapies.
Background
Glioblastoma multiforme (GBM) remains one of the deadliest cancers due to its complex and highly heterogeneous nature. Current standard-of-care treatments often fall short, leading to poor clinical outcomes. Advances in targeted therapy offer a beacon of hope by exploiting specific receptors overexpressed on the surface of GBM cells. This approach aims to deliver therapeutics precisely to tumor sites, minimizing off-target effects and improving efficacy where conventional methods struggle with issues like blood-brain barrier (BBB) penetration and systemic toxicity.
Study Design
This comprehensive review systematically analyzed literature from PubMed and Google Scholar published between 2006 and 2026. The authors focused on identifying and characterizing receptors overexpressed on glioblastoma multiforme (GBM) cells, exploring their potential as biomarkers for targeted therapy. The review evaluated various nanoparticle platforms, including liposomes and gold nanoparticles, functionalized with targeting ligands such as Pep-1L, lactoferrin, and RGD peptides, and loaded with anticancer drugs like temozolomide and gefitinib. The scope included preclinical outcomes and early-phase clinical trials.
Results
The review highlighted several key receptors overexpressed on GBM cells, including interleukin-13 receptor alpha 2 (IL-13Rα2), transferrin receptor (TfR), receptor tyrosine kinases (RTKs), and integrins, as promising targets for precision therapy. Nanoparticles such as liposomes, lactoferrin-based nanocarriers, and gold nanoparticles functionalized with ligands like Pep-1L, lactoferrin, and RGD peptides demonstrated promising preclinical outcomes when loaded with anticancer drugs like temozolomide, gefitinib, and epirubicin. Several of these formulations are currently in early-phase clinical trials, evaluating safety, pharmacokinetics, and therapeutic efficacy. > The review also identified periostin (POSTN) and chondroitin sulfate proteoglycan-4 (CSPG4) as underexplored receptors involved in tumor invasion, glioma stemness, and therapeutic resistance, presenting significant opportunities for future research.
Key Findings
- IL-13Rα2, TfR, RTKs, and integrins are consistently overexpressed on glioblastoma cells, making them prime targets for therapy.
- Nanoparticles (liposomes, gold nanoparticles) functionalized with ligands like Pep-1L, lactoferrin, and RGD peptides show promising preclinical results in targeted GBM drug delivery.
- Anticancer drugs such as temozolomide, gefitinib, and epirubicin can be effectively delivered via these targeted nanoparticle systems.
- Periostin (POSTN) and chondroitin sulfate proteoglycan-4 (CSPG4) are underexplored receptors involved in GBM invasion and resistance, warranting further investigation.
- Despite preclinical success, nanoparticle cytotoxicity and off-target effects remain significant hurdles for clinical translation.
Why It Matters
This review underscores the critical role of targeted therapies in overcoming the challenges of glioblastoma multiforme (GBM), offering a roadmap for future drug development. Identifying and leveraging specific overexpressed receptors on GBM cells is crucial for developing more effective and less toxic treatments. For peptide users and biohackers, this highlights the potential of specific peptide ligands, like RGD peptides and Pep-1L, in guiding therapeutic delivery. Clinical translation, however, remains limited by nanoparticle-associated cytotoxicity and off-target effects, emphasizing the need for developing more biodegradable and biocompatible nanomaterials with optimized ligand-guided designs to enhance safety and translational feasibility.
glioblastoma
targeted-therapy
nanoparticles
il-13ra2
tfr
rtk